Reports Q3 revenue $2.8M vs $2.6M last year. Tracy Curley, Chief Executive Officer of iSpecimen, stated, “Our third quarter results highlight the success of our efforts to improve operational efficiencies. I am extremely encouraged by the positive turnaround of our results in the third quarter compared to the second quarter, which combined with our recent cost cutting initiatives, adds to my belief that we are on track with our target to become cash flow neutral by year end.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ISPC:
- iSpecimen Reports Third Quarter 2023 Financial and Operating Results
- iSpecimen expands provider network to advance infectious disease research
- iSpecimen Preannounces Third Quarter 2023 Revenue Increase of 60-70% Sequentially
- iSpecimen sees Q3 revenue $2.6M-$2.8M vs. $1.63M last year
- iSpecimen Launches Next-Day Quote Service for Medical Researchers and Biospecimen Providers